ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer

被引：0
|
作者：
J. A. Kyte
A. Røssevold
R. S. Falk
B. Naume
机构：
[1] Oslo University Hospital,Department of Clinical Cancer Research
[2] Oslo University Hospital,Department of Cancer Immunology
[3] Oslo University Hospital,Department of Oncology
[4] Oslo University Hospital,Oslo Centre for Biostatistics and Epidemiology
[5] University of Oslo,Institute of Clinical Medicine
来源：
Journal of Translational Medicine | / 18卷
关键词：
Breast cancer; Triple negative; Immunotherapy; Checkpoint inhibitor; Immunogenic cell death; PD-1; PD-L1; Anthracycline; Cyclophosphamide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] A randomized, phase II, multicenter, double-blind, placebo-controlled trial evaluating onartuzumab with or without bevacizumab in combination with weekly paclitaxel in locally recurrent or metastatic triple-negative breast cancer (TNBC)
    Dieras, V.
    Yardley, D.
    Romieu, G.
    Valero, V.
    Isakoff, S.
    Koeppen, H.
    Thurm, H.
    Teng, M.
    Campone, M.
    Mocci, S.
    CANCER RESEARCH, 2013, 73
  • [22] Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031)
    Saji, Shigehira
    Ohsumi, Shozo
    Ito, Mitsuya
    Hayashi, Naoki
    Kobayashi, Kokoro
    Masuda, Norikazu
    Niikura, Naoki
    Yamashita, Toshinari
    Kiyama, Keiichiro
    Hasegawa, Ayumi
    Nakagawa, Shizuka
    Hattori, Masaya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (10) : 1124 - 1133
  • [23] A Prospective, Randomized, Placebo-Controlled Study of a Combination of Simvastatin and Chemotherapy in Metastatic Breast Cancer
    Alarfi, Hiba
    Youssef, Lama A.
    Salamoon, Maher
    JOURNAL OF ONCOLOGY, 2020, 2020
  • [24] A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer
    Garrido-Castro, Ana C.
    Graham, Noah
    Bi, Kevin
    Park, Jihye
    Fu, Jingxin
    Keenan, Tanya
    Richardson, Edward Thomas
    Pastorello, Ricardo
    Lange, Paulina
    Attaya, Victoria
    Wesolowski, Robert
    Sinclair, Natalie
    Lucas, Zarah
    Lo, Steve
    Tung, Nadine
    Faggen, Meredith
    Kaufman, Peter A.
    Block, Caroline C.
    Briccetti, Fred
    Toke, Madhavi
    Chen, Wendy
    Wucherpfennig, Kai
    Marx, Sascha
    Agudo, Judith
    Guerriero, Jennifer L.
    Schnitt, Stuart
    Lin, Nancy U.
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Tayob, Nabihah
    Van Allen, Eliezer
    Tolaney, Sara M.
    CANCER RESEARCH, 2022, 82 (04)
  • [25] Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
    Joyce O’Shaughnessy
    Adam Brufsky
    Hope S. Rugo
    Sara M. Tolaney
    Kevin Punie
    Sagar Sardesai
    Erika Hamilton
    Delphine Loirat
    Tiffany Traina
    Roberto Leon-Ferre
    Sara A. Hurvitz
    Kevin Kalinsky
    Aditya Bardia
    Stephanie Henry
    Ingrid Mayer
    Yanni Zhu
    See Phan
    Javier Cortés
    Breast Cancer Research and Treatment, 2022, 195 : 127 - 139
  • [26] IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer
    Cortes, Javier
    Andre, Fabrice
    Goncalves, Anthony
    Kuemmel, Sherko
    Martin, Miguel
    Schmid, Peter
    Schuetz, Florian
    Swain, Sandra M.
    Easton, Valerie
    Pollex, Erika
    Deurloo, Regula
    Dent, Rebecca
    FUTURE ONCOLOGY, 2019, 15 (17) : 1951 - 1961
  • [27] Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
    O'Shaughnessy, Joyce
    Brufsky, Adam
    Rugo, Hope S.
    Tolaney, Sara M.
    Punie, Kevin
    Sardesai, Sagar
    Hamilton, Erika
    Loirat, Delphine
    Traina, Tiffany
    Leon-Ferre, Roberto
    Hurvitz, Sara A.
    Kalinsky, Kevin
    Bardia, Aditya
    Henry, Stephanie
    Mayer, Ingrid
    Zhu, Yanni
    Phan, See
    Cortes, Javier
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 195 (02) : 127 - 139
  • [28] FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer
    Oliveira, M.
    Saura, C.
    Nuciforo, P.
    Calvo, I
    Andersen, J.
    Passos-Coelho, J. L.
    Gil Gil, M.
    Bermejo, B.
    Patt, D. A.
    Ciruelos, E.
    de la Pena, L.
    Xu, N.
    Wongchenko, M.
    Shi, Z.
    Singel, S. M.
    Isakoff, S. J.
    ANNALS OF ONCOLOGY, 2019, 30 (08) : 1289 - 1297
  • [29] A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer
    Huang, Jia-Yi
    Xie, Xiao-Feng
    Chen, Xue-Lian
    Zhang, Qiu-Yi
    Chen, Li-Ping
    Bai, Xue
    Lan, Xiao-Feng
    Song, Lin
    Guo, Jin-Feng
    Du, Cai-Wen
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [30] ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
    J. A. Kyte
    N. K. Andresen
    H. G. Russnes
    S. Ø. Fretland
    R. S. Falk
    O. C. Lingjærde
    B. Naume
    Journal of Translational Medicine, 18
12345